Wire flash
Yipinhong Subsidiary Gets Drug Registration for Compound Polyethylene Glycol Oral Solution for Constipation
Editorial responsibility
- No named human review is recorded for this page.
- Source reporting is collected, normalized, translated or condensed automatically when needed.
- Automatically published source-backed update
On September 20, Yipinhong Pharmaceutical Co., Ltd. announced that its subsidiary has received the Drug Registration Certificate for Compound Polyethylene Glycol (3350) Electrolyte Oral Solution, approved by China's National Medical Products Administration. The approval qualifies the company to sell this drug specification in the domestic market, enriching its product pipeline and enhancing competitiveness in the chronic disease medication sector. The drug is indicated for treating constipation and fecal impaction. According to data from Menet, polyethylene glycol sales in China's urban and county hospitals are projected to reach a certain level by 2025. The report also notes that by mid-2026, Yipinhong achieved revenue of RMB 492 million and net profit attributable to shareholders of the parent company of RMB 485 million. The source is Caizhong She via East Money.
Source report
September 20 — Yipinhong Pharmaceutical Co., Ltd. has recently obtained the Drug Registration Certificate for Compound Polyethylene Glycol (3350) Electrolyte Oral Solution, approved and issued by the National Medical Products Administration.
The approval of this drug registration certificate confirms that the company is qualified to market this specification of the drug in the domestic market. This development further enriches the company's product pipeline and strengthens its competitiveness in the chronic disease medication sector.
According to the announcement, the indications for Compound Polyethylene Glycol (3350) Electrolyte Oral Solution include the treatment of constipation and fecal impaction. Data from Menet projects that by 2025, polyethylene glycol sales in China's urban and county hospitals will...
In mid-2026, Yipinhong reported revenue of RMB 492 million and net profit attributable to shareholders of the parent company of RMB 485 million.
Source: Caizhong She
Source
东方财富网-公司报道Eastern
Part of this Story
Yipinhong subsidiary gains NMPA approval for polyethylene glycol constipation drug